射频消融已用于治疗肝脏、肺部、肾脏及肾上腺的实体肿瘤。近期，EUS引导RFA已可供使用，该装置允许以EUS引导治疗腹部实体肿瘤。此程序已在猪胰腺中显示可行，并曾用于治疗小群不适合手术的胰腺癌患者。 本研究的目的在于进行一项
适应症：Digestive System Neoplasms
入组条件
纳入标准
- Age 18 years-old or above
- Suffering from solid neoplasms of the stomach, liver, kidney or adrenals (\<5cm in largest diameter) that is indicated for treatment.
- Unsuitable for surgery, due to one (or more) of the following items:
- ASA score \> II\*
- An alternative advanced malignancy
- Unsuitable for surgery upon expert's opinion for any other reason
- Healthy individuals who are not keen for surgical resection
- Eligible for endoscopic intervention
- Written informed consent
排除标准
- Coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
- Pregnancy
- Patients with a poor mental condition or mental retardation, unable to understand the nature and possible consequences of the study
- Patients unwilling to undergo follow-up assessments
- Patients with liver cirrhosis, portal hypertension and/or gastric varices.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。